Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v3.8.0.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2017
Jun. 30, 2017
Current assets:    
Cash $ 7,310 $ 8,088
Accounts receivable - trade 136 175
Work in process 0 26
Prepaid expenses and other current assets 377 283
Total Current Assets 7,823 8,572
Fixed assets, net of accumulated depreciation 25,289 25,589
Intangible assets, net of accumulated amortization 1,702 1,823
Security deposit 26 26
Total Assets 34,840 36,010
Current liabilities:    
Accounts payable (related party of $83 and $87 as of December 31, 2017 and June 30, 2017, respectively) 701 749
Accrued expenses (related party of $911 and $650 as of December 31, 2017 and June 30, 2017, respectively) 1,130 924
Capital lease obligation - current portion 190 183
Deferred revenue 23 157
Total Current Liabilities 2,044 2,013
Capital lease obligation - net of current portion 24,985 25,082
Total Liabilities 27,029 27,095
Commitments and Contingencies
iBio, Inc. Stockholders' Equity:    
Preferred stock - $0.001 par value; 1,000,000 shares authorized; 1 share issued and outstanding as of both December 31, 2017 and June 30, 2017 0 0
Common stock - $0.001 par value; 275,000,000 and 175,000,000 shares authorized as of December 31, 2017 and June 30, 2017, respectively, 115,318,510 and 89,118,510 shares issued and outstanding as of December 31, 2017 and June 30, 2017, respectively 115 89
Additional paid-in capital 87,574 80,977
Accumulated other comprehensive loss (29) (29)
Accumulated deficit (79,848) (72,123)
Total iBio, Inc. Stockholders' Equity 7,812 8,914
Noncontrolling interest (1) 1
Total Equity 7,811 8,915
Total Liabilities and Equity $ 34,840 $ 36,010